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Background: Alternative splicing of pre-mRNA transcripts not only plays a role in normal molecular processes but is also
associated with cancer development. While normal transcripts are ubiquitously expressed in normal tissues, splice variants
created through abnormal alternative splicing events are often expressed in cancer cells. Although the Rho GDP
dissociation inhibitor β (ARHGDIB) gene has been found to be ubiquitously expressed in normal tissues and involved in
cancer development, the presence of splice variants of ARHGDIB has not yet been investigated.
Results: Validation analysis for the presence of and exon structures of splice variants of ARHGDIB, performed using
reverse-transcriptase polymerase chain reaction and DNA sequencing, successfully identified novel splice variants of
ARHGDIB, that is, 6a, 6b, and 6c, in colon, pancreas, stomach, and breast cancer cell lines. Quantitative real-time
polymerase chain reaction analysis showed that these variants were also highly expressed in normal placental tissue but
not in other types of normal tissue.
Conclusions: Expression of ARHGDIB variants 6a, 6b, and 6c appears to be restricted to cancer cells and normal placental
tissue, suggesting that these variants possess cancer-specific functions and, as such, are potential cancer-related
biomarkers.
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Alternative splicing of pre-mRNA transcripts is an impor-
tant process by which genomic complexity is generated
from the small number of genes currently estimated to be
present within the human genome sequence. Alternative
splicing not only plays a role in normal molecular processes
but is also associated with cancer development [1-5]. While
normal transcripts are ubiquitously expressed in normal
tissues [6,7], splice variants created through abnormal alter-
native splicing events are often expressed in cancer cells.
When the different expression patterns of a splice variant
and the normal transcript on the same gene can be
detected, the variant is considered a potential biomarker.* Correspondence: k.hatakeyama@scchr.jp
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distribution, and reproduction in any mediumThe Rho GDP dissociation inhibitor β gene, commonly
referred to as ARHGDIB but also known as LyGDI,
GDI-D4, RhoGDI2, or RhoGDIβ, inhibits dissociation of
GDP from Rho family GTPases. ARHGDIB has been
reported to be involved in either the progression or sup-
pression of metastasis [8-17] and is also ubiquitously
expressed in normal tissues [11]. Despite these recent
findings, the presence of splice variants of ARHGDIB in
cancerous cell lines has not yet been investigated. Employ-
ing validation analysis using RT-PCR and DNA sequencing,
this study aimed to fill this research gap by investigating
alternative splicing events in cancer cell lines and normal
tissues to identify splice variants of ARHGDIB. The analysis
showed the presence of 3 novel splice variants of the
ARHGDIB gene, and their expression was observed only in
cancer cell lines and normal placenta. However, no protein
isoforms were translated from these variants since their
protein-coding regions were identical.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Cell lines and culture conditions
The cell lines used in this study are listed in Additional file
1: Table S1. The MKN45P cell lines [18] were kindly
provided by Dr. Yutaka Yonemura and Dr. Yoshio Endo.
These cell lines were cultured and maintained in RPMI
1640, DMEM/F12, or DMEM medium (Sigma-Aldrich, St.
Louis, MO, USA) supplemented with 5–10% foetal bovine
serum (FBS; Invitrogen, Carlsbad, CA, USA), glutamine
(0.3 mg/ml), penicillin (100 unit/ml), and streptomycin
(0.1 mg/ml), in a humidified 5% CO2 incubator. Protein
expression and mRNA analyses were performed using cells
found to have 70–90% confluency and greater than 95%
viability, as determined using trypan blue staining.
RNA extraction and cDNA synthesis
After total RNA had been extracted from each pellet using
the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany), RNA
concentration was determined using a NanoDrop spectro-
photometer (Thermo Fisher Scientific, Waltham, MA,
USA), and total RNA quality was then confirmed using the
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). The purified total RNA from cancer cell
lines and total RNA derived from normal tissues (Clontech,
Mountain View, CA, USA) were then reverse-transcribed
using ThermoScript Reverse Transcriptase (Invitrogen) and
oligo(dT)20 primers in accordance with the manufacturer’s
instructions. The normal tissues that were purchased are
listed in Additional file 1: Table S2.
Reverse-transcriptase PCR
Screening of cDNA for different splice variants of
ARHGDIB was performed using the intron-spanningTable 1 DNA sequences of RT-PCR, quantitative RT-PCR, and
Target Sense primer (location)
RT-PCR and DNA sequencing
NM_001175 ACTCAGAAGTCAGAGTTGAGAGAC (exon 1)





ACTB ATTCCTATGTGGGCGACGAGGC (exon 3)
Quantitative RT-PCR
NM_001175 GGACAGAGACGTGAAGCACTGA (exon 1)
variant 6a GTCTTTGTGCCATGTTGCTTCA (exon 1x/y/z)
ACTB TGGCACCCAGCACAATGA (exon 5)
Standard curves in quantitative RT-PCR
NM_001175 ACTCAGAAGTCAGAGTTGAGAGAC (exon 1)
variant 6a ACTGGGCTTTTGCTTCATTTGTTCAG (exon 1x/y/exonic primers listed in Table 1. PCR amplicons were
designed to detect the splice variants and the transcript
registered in GenBank. The cDNA synthesized was ampli-
fied using LA Taq polymerase (Takara Bio, Shiga, Japan)
with 35 PCR cycles of 95°C for 30 sec, 51°C for 30 sec, and
68°C for 60 sec.
Rapid amplification of cDNA ends and DNA sequencing
analysis
To determine the sequence of novel ARHGDIB transcripts,
rapid amplification of cDNA ends (RACE) was conducted
using the GeneRacer Kit (Invitrogen) according to the man-
ufacturer’s instructions. The primer sequences are shown in
Table 1. For DNA sequencing analysis, the PCR products
were analysed on 1–2% agarose gels by electrophoresis
following by gel staining with SYBR Safe (Invitrogen). The
bands visualized under ultraviolet light were isolated and
purified using the QIAquick Gel Extraction Kit (Qiagen).
The purified samples were then cloned into a pCR
2.1-TOPO vector (Invitrogen) using the TOPO TA Cloning
Kit for Sequencing (Invitrogen). Positive transformants
were sequenced using the Big Dye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, USA)
and an ABI 3130xl Genetic Analyzer (Applied Biosystems).
The start and stop codons were determined from the iden-
tified sequences and are shown in Figure 1B.
Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was performed
using the SYBR Green dye technique and the ABI PRISM
7900HT Fast Real Time PCR System (Applied Biosystems).
The target fragment among the synthesized cDNA was
amplified using specific primers (Table 1) according to theDNA sequencing primers
Antisense primer (location)
AGAGAATTCTTCCAGGTGGCAAGG (exon 6/6x)
z) AGAGAATTCTTCCAGGTGGCAAGG (exon 6/6x)
ACGAGTGAAGCAACATGGCACAAAG (exon 1x/y/z)
z) GCTGTCAACGATACGCTACGTAACG (30 RACE)
y/z) CGCTACGTAACGGCATGACAGTG (30 RACE)






z) ACTCTCACAAACCAGGGTGAGC (exon 3)
Figure 1 (See legend on next page.)
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Figure 1 ARHGDIB expression pattern in cell lines and normal tissues. (A) ARHGDIB expression profile in colon, pancreas, stomach, and
breast cancer cell lines. Amplicons (i), (ii), (iii), and (iv) correspond to the 4 types of transcripts shown in Panel B. (B) Exon structures on the
ARHGDIB gene. The 5 forms shown include the known transcript NM_001175 (i), 3 novel variants (ii–iv), and the known variant ARHGDIB-006
predicted in Ensembl (v). The grey boxes show novel alternative splicing forms in variant 6a (ii), 6b (iii), and 6c (iv). The † and * symbols indicate
the locations of the start codon and the stop codon, respectively. The number of exons is shown on the white and grey boxes. Primer positions
for RT-PCR and qRT-PCR are indicated by black and grey arrows, respectively.
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at 95°C for 1 sec and 60°C for 30 sec; and dissociation at
95°C for 15 sec, 60°C for 15 sec, and 95°C for 15 sec. The
threshold cycle (Ct) values were converted into absolute
copy numbers using a standard curve. This standard curve
was constructed using data for purified PCR amplicons
that were generated from the plasmids containing the
sequences of the target transcripts. These conversions for
quantification were performed for data obtained at high
PCR amplification efficiencies (95–105%). Nonspecific
amplification in qRT-PCR was checked by dissociation
curve analysis and gel electrophoresis, which showed the
amplicon size.
Immunoblotting
SW948, Colo741, and DLD-1 cells were harvested using a
trypsin–EDTA solution (Invitrogen) and washed twice with
phosphate-buffered solution (PBS, pH 7.4). After removal
of the supernatant, cellular pellets were ultrasonicated in
PBS with a protease inhibitor cocktail (Roche Diagnostics,
Basel, Switzerland). Centrifugation of the lysates at 15,000 g
for 10 min was followed by collection of the supernatant
for determination of protein concentration using the Quick
Start Bradford Protein Assay Kit (Bio-Rad, CA, USA). The
quantified lysates were then subjected to one-dimensional
sodium dodecyl sulphate-polyacrylamide gel electropho-
resis (SDS-PAGE) using 5 μg of lysate protein/well on
12.5% polyacrylamide gel. After electroblotting of the lysate
onto polyvinylidene difluoride membranes (pore size,
0.45 μm; Millipore, Bedford, MA, USA), the blots were
probed with a mouse monoclonal anti-ARHGDIB/D4-GDI
antibody (1:500 dilution; Acris Antibodies GmbH, Herford,
Germany) and a rabbit polyclonal anti-TUBA4A antibody
(1:5,000 dilution; Santa Cruz Biotechnology, Santa Cruz,
CA, USA). The bound antibodies were incubated with the
corresponding anti-IgG secondary antibodies conjugated
with horseradish peroxidase (1:50,000 dilution; Jackson
Laboratories, Bar Harbor, ME, USA). Specific proteins were
visualized using the ECL Plus Western Blotting Detection
System (GE Healthcare, Little Chalfont Buckinghamshire,
England) and the FUJIFILM Luminescent Image Analyzer
LAS3000 (Fuji Film, Tokyo, Japan).
mRNA stability assay
To assay mRNA stability, actinomycin D was added to the
culture medium when the SW948 cells reached 80–90%confluence. During the following 24 h, cells were har-
vested at 0, 2, 4, 6, 8, 10, or 24 h, and total RNA was
extracted as described above. The amount of target tran-
scripts (known form of ARHGDIB and variant 6a) and
actin β (ACTB) at each time point was quantified using
qRT-PCR.
Results
Identification of novel ARHGDIB exons
ARHGDIB is known to be involved in the progression of
metastasis [10,12,14-17] in colon, pancreas, stomach, and
breast cancer. Therefore, systematic RT-PCR screening of
46 cancer cell lines and of normal colon, pancreas,
stomach, breast, and placental tissue was conducted using
newly designed RT-PCR primers for several exons on the
target gene and a primer pair spanning the region from
exon 1 to exon 6 on the known ARHGDIB transcript
registered in GenBank (NM_001175; Figure 1A). RT-PCR
screening revealed positive signals (i) in 36 cell lines (78%)
and all 4 types of normal tissue whose lengths were identi-
cal to those of the known transcript. The RT-PCR subse-
quently performed using another primer pair designed for
annealing within exon 1 of the variant ARHGDIB-006
(ENST00000541644), which is predicted in the Ensembl
and Havana models (http://www.ensemb.org), did not
result in detection of the expected band. Likewise, other
splice forms whose detection had been anticipated were
not observed. Although other bands (ii–iv) were observed
in 35 cell lines (76%), these bands were not detected in all
the normal tissues. These results indicate that the
unknown ARHGDIB transcripts are expressed along with
the known ubiquitously expressed ARHGDIB transcripts
only in cancer cells.
To determine the exon structures of the unknown
transcripts (ii-iv), designated as variants 6a, 6b, and 6c,
respectively (Figure 1B), DNA sequencing was performed
using RACE. Although the spliced forms were found to
consist of 6 exons, as seen in the predicted variant
(ARHGDIB-006), their first and last exons differed from
those of the predicted variant (Figure 1B). Specifically, the
first exons (exon 1x–z) were derived from the intronic re-
gion in the known transcript and the sixth exons (exon 6x)
from a part of exon 6 identical to the known transcript,
while exons 2 to 5 were common in all the novel tran-
scripts. Although the exon structures of these novel and
known variants, along with the known transcript, were
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protein-coding regions.ARHGDIB splice variants in normal tissues
Novel splice variants were detected in colon, pancreas,
stomach, and breast cancer cells but not in the
corresponding normal tissues. To verify the cancer specifi-
city of these variants, their mRNA expression profile in
other normal tissues was investigated using qRT-PCR
(Figure 2). As shown in Figure 1A, all 3 variants were
expressed in most of the cancer cell lines (6a–c), which
appeared to express variant 6a at the highest level. The
mRNA expression level of variant 6a was examined on the
basis of these results. Normal ARHGDIB expression was
found to be ubiquitous in the normal tissues analysed, con-
sistent with previously reported results [11]. In contrast,
mRNA expression of variant 6a was only detected in pla-
cental tissue, while the amount of variant 6a transcript in
the other normal tissues was below the detection limit of
qRT-PCR. These results indicate that the cancer-specificFigure 2 Comparison of splicing events in normal tissues. The copy nu
values obtained by qRT-PCR analysis performed in duplicate. The left and r
variant 6a, respectively.splice variants identified in this study are also expressed in
normal placental tissue.
Validation of ARHGDIB mRNA and protein expression levels
Despite significant differences in the 50 and 30 untranslated
regions (UTRs) between the known ARHGDIB transcript
and the variant 6 series (6a, 6b, and 6c), the sequences of
their protein coding regions were found to be identical in
all the transcripts examined. Validation of mRNA and
protein expression levels was conducted using Colo741,
DLD-1, and SW948, colon cancer cell lines that have
shown discriminating patterns of mRNA expression
(Figure 1A). Specifically, Colo741 has been found to highly
express the known transcript, DLD-1 has been found to ex-
press only the novel variants, and SW948 has been found
to express both transcripts. To quantify their mRNA levels
more precisely, qRT-PCR analysis was first performed. The
mRNA level of variant 6a was reflected in the visualized
image of the RT-PCR amplicons (Figure 3A), and the ex-
pression patterns of variants 6b and 6c in the 3 cell lines
were found to be similar to that of variant 6a (data notmber of transcripts was estimated by determining the mean of the
ight panels show the expression patterns of normal ARHGDIB and
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DIB protein level led to recognition of the amino acid se-
quence positioned between 125 and 137 in the target
protein by the ARHGDIB antibody used in this study
(Figure 3B). As the protein-coding region of the identified
variants was found to be identical to that of the normal
ARHGDIB transcript, the stained protein in the immuno-
blots was considered to have been translated from both
the normal and variant RNA. Nevertheless, the expression
levels of this protein in the 3 cell lines were proportional
to those of the mRNA levels of the normal transcript. Al-
though the mRNA expression of variant 6a was higher inFigure 3 Expression analysis of ARHGDIB at the mRNA and
protein levels in colon cancer cell lines. (A) The expression levels
of known ARHGDIB transcripts and variant 6a transcripts were
analysed by qRT-PCR. (B) Protein expression was confirmed by
immunoblotting with the ARHGDIB-specific monoclonal antibody.
Immunoblotting of tubulin, α 4a (TUBA4A) protein, was conducted
as a positive control experiment. The colon cancer cell lines Colo741,
DLD-1, and SW948 were examined as representative cancer cell lines
whose expression profiles of variant 6a differs from that of the
normal transcript. Data are expressed as mean ± SD values
calculated from information obtained from an experiment repeated
4 times. Statistical significance (*p < 0.05 and **p < 0.01) was
evaluated by Student’s t-test.DLD-1 than in SW948, the ARHGDIB protein expression
levels in both cell lines were inversely correlated with the
transcript levels. These results raise the possibility that the
translation of variant 6a into intact protein is partially sup-
pressed through the alteration of exon structures.
Stability of variant 6a mRNA
The stability of mRNA, which regulates protein expression,
is affected by UTR variation through alternative splicing
[19,20]. To evaluate the mRNA stability of variant 6a, the
half-life of normal ARHGDIB mRNA and that of variant 6a
mRNA was determined in SW948 cells that equally
expressed both forms of mRNA. To inhibit transcription,
SW948 cells were treated with actinomycin D, while
amplification of ACTB was conducted as a positive control
experiment. The relative expression levels of normal
ARHGDIB mRNA and variant 6a mRNA in SW948 cells
treated without actinomycin D remained stable during 24 h
of observation (Figure 4A), and their half-life values were
estimated to be 8 h and 1 h, respectively (Figure 4B). These
results suggest that the mRNA stability of variant 6a is
lower than that of normal ARHGDIB.
Discussion
Alternative splicing, a phenomenon by which a single gene
generates multiple forms of mRNA that can be translated
into diverse proteins [21], is responsible for an estimated
10–20% of all cancer-related gene alterations [5,22,23].
Both the ubiquitous normal transcripts and the unique
splice variants generated from these alteration events are
frequently expressed simultaneously in cancerous cells and
tissues [6,7,24]. As such, those variants expressed as
cancer-specific transcripts are possible candidate biomar-
kers [6,7]. This study revealed that while the splice variants
6a, 6b, and 6c of the ARHGDIB gene are expressed in
pancreas, stomach, colon, and breast cancer cell lines and
in normal placental tissue but not in other types of normal
tissue, the known form of ARHGDIB is ubiquitously
expressed in many types of normal tissue and cancer cells.
A similarly restricted profile has also been observed for
PLAC1. PLAC1, reported to be the first member of a new
class of antigens that specifically relates placentation to
cancer [25,26], has been observed to be ectopically acti-
vated in many human cancers and is essentially involved in
malignant cell processes [25]. These ARHGDIB variants
can be considered potential biomarkers based on the simi-
larity between ARHGDIB and PLAC1 reported in previous
studies, as well as the observation of high levels of expres-
sion of the variants 6a, 6b, and 6c in placental and cancer
cells and their relatively restricted expression in normal
tissues in this study.
Splice variants are often translated into structurally
defective proteins in cancer cells, affecting the functioning
of the original protein [7,27]. In a previous study, the
Figure 4 Stability of ARHGDIB variant 6a mRNA and normal
ARHGDIB mRNA. SW948 cells were cultured without (A) or with (B)
actinomycin D (ActD). Amplification of actin β (ACTB) was conducted
as a positive control experiment. The expression levels of transcripts
before addition of ActD are shown as 100%. Data are expressed as
mean ± SD values calculated from information obtained from an
experiment repeated 4 times. Statistical significance (**p < 0.01) was
evaluated by Student’s t-test.
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and variant-derived protein isoforms to identify candidate
biomarkers [6]. However, the current study revealed that
the variants 6a, 6b, and 6c and the normal transcript share
a common protein-coding region and that these variants
are slightly translated into the intact ARHGDIB protein.
These results suggest that the structurally defective
protein isoforms of ARHGDIB derived from the variant 6
series are not expressed in cancer cells and the placenta,
thereby indicating that the mRNA of the cancer-specific
variant 6 series may be a more suitable biomarker than
the ARHGDIB protein.
In general, mRNA stability is related to UTR length as
well as secondary structure [20], as both influence the
regulation of protein expression [19]. In this study, the50 and 30 UTRs of the variant 6 series were observed to
clearly differ from those of the normal ARHGDIB, resulting
in the decreased mRNA stability of these variants, while the
translation efficiency of the variants into intact ARHGDIB
protein was observed to be distinctly low. These findings
suggest that the mRNA stability of the novel variants
identified in this study may be involved in the regulation of
protein expression.
Conclusions
In summary, validation analysis using RT-PCR and DNA
sequencing successfully identified variants 6a, 6b, and
6c—3 novel splice variants of the ARHGDIB gene—in
colon, pancreas, stomach, and breast cancer cell lines;
these variants were also found to be highly expressed in
normal placental tissue. In contrast, the mRNA expression
of known ARHGDIB was ubiquitous in many normal
tissues and cancer cells. These findings suggest that these
cancer and placenta-specific variants possess cancer-
specific functions and, as such, are potential cancer-
related biomarkers.
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